Days Inventory is also known as Days Sales of Inventory (DSI). NextCure's Average Total Inventories for the
three
months ended in Dec. 2024 was $0.00 Mil. NextCure's Cost of Goods Sold for the
three
months ended in Dec. 2024 was $0.00 Mil.
The historical rank and industry rank for NextCure's Days Inventory or its related term are showing as below:
NXTC's Days Inventory is not ranked *
in the Biotechnology industry.
Industry Median: 181.485 * Ranked among companies with meaningful Days Inventory only.
NextCure's Days Inventory
stayed the same
from Dec. 2023 (0.00) to Dec. 2024 (0.00).
Inventory Turnover measures how fast the company turns over its inventory within a year.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
NextCure Days Inventory Historical Data
The historical data trend for NextCure's Days Inventory can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of NextCure's Days Inventory
For the Biotechnology subindustry, NextCure's Days Inventory, along with its competitors' market caps and Days Inventory data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
NextCure's Days Inventory Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, NextCure's Days Inventory distribution charts can be found below:
* The bar in red indicates where NextCure's Days Inventory falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NextCure (NAS:NXTC) Days Inventory Explanation
Days Inventory indicates the liquidity of the inventory. Generally, a lower Days Inventory is preferred as it indicates a shorter duration to clear off the inventory. An increase of the ratio may indicate the company's sales slowed. Similar ratios related to Days Inventory are:
1. Inventory Turnover measures how fast the company turns over its inventory within a year.
NextCure's Inventory Turnover for the
three
months ended in Dec. 2024 is calculated as
2. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
NextCure's Inventory to Revenue for the
three
months ended in Dec. 2024 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
A lot of business are seasonable. It makes more sense to compare Days Inventory from the same period in the previous year instead of from the previous quarter.
NextCure Days Inventory Related Terms
Thank you for viewing the detailed overview of NextCure's Days Inventory provided by GuruFocus.com. Please click on the following links to see related term pages.
NextCure Inc is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company's product candidates include; NC410 a fusion protein of LAIR-2, a fusion protein that, in combination with pembrolizumab, demonstrated early evidence of clinical activity in colorectal (CRC) and ovarian cancers, and LNCB74, an ADC that is directed to B7-H4, a clinically validated cancer target. The company is also seeking a partner for its other clinical programs such as NC525 and NC318 and its preclinical non-oncology programs NC605, for chronic bone diseases and NC181, for Alzheimer's disease.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
NXTC has been successfully added to your 